8-K Announcements
6Material company update
May 19, 2026·SEC
Material company update
May 14, 2026·SEC
Material company update
Apr 9, 2026·SEC
Cardiff Oncology, Inc.(CRDF)Earnings, Financials & Key Ratios
CRDF•NASDAQ
Price updated Jun 11, 2026
AboutCardiff Oncology, Inc., a clinical-stage oncology company, develops medicine treatment for cancer patients in California. Its lead drug candidate is onvansertib, an oral selective Polo-like Kinase 1 Inhibitor for anti-cancer therapeutics; CY140, an inhibitor of PLK1, PLK2, and PLK3 that is in phase 1/2 studies in solid tumors and leukemias; metastatic colorectal cancer that is in clinical trials; and TROV-054 is a Phase 1b/2 for FOLFIRI and bevacizumab. The company's TROV-053 is also in Phase II clinical trial in combination with Zytiga for metastatic castration-resistant prostate cancer. The company primarily serves pharmaceutical manufacturers. The company was formerly known as Trovagene, Inc. and changed its name to Cardiff Oncology, Inc. in May 2012. Cardiff Oncology, Inc. was incorporated in 1999 and is headquartered in San Diego, California.Show more
- Revenue$593K-13.2%
- EBITDA-$48M+0.4%
- Net Income-$46M-0.9%
- EPS (Diluted)-0.69+27.4%
- Gross Margin100%
- EBITDA Margin-8103.88%-14.7%
- Operating Margin-8256.32%-15.9%
- Net Margin-7732.04%-16.2%
- ROE-71.45%-20.1%
- ROIC-118.93%-35.6%
- Debt/Equity0.02-0.2%
CRDF Key Insights
Cardiff Oncology, Inc. (CRDF) fundamental analysis — strengths, weaknesses & financial health based on data analysis
✓Strengths
- ✓Company is almost debt free
- ✓Strong 5Y sales CAGR of 10.1%
✗Weaknesses
- ✗Profits declining 18.9% over 5 years
- ✗Weak Piotroski F-Score: 3/9
- ✗Negative free cash flow
- ✗Shares diluted 40.3% in last year
- ✗Trading more than 30% below 52-week high
- ✗Low asset turnover indicates capital-intensive operations
* These insights are generated automatically based on available financial data. Please conduct your own research before making investment decisions.
Get notified when CRDF posts new earnings or crosses analyst targets
Free. No account needed. Unsubscribe any time.
CRDF Price & Volume
Cardiff Oncology, Inc. (CRDF) stock price & volume — 10-year historical chart
Loading chart...
CRDF Growth Metrics
Cardiff Oncology, Inc. (CRDF) revenue, earnings & EPS growth — 3, 5 & 10-year CAGR
Revenue CAGR
10 Years6.6%
5 Years10.13%
3 Years15.39%
TTM-10.71%
Profit CAGR
10 Years-
5 Years-
3 Years-
TTM8.36%
EPS CAGR
10 Years-
5 Years-
3 Years-
TTM35.58%
Return on Capital
10 Years-81.13%
5 Years-48.42%
3 Years-63.04%
Last Year-75.76%
CRDF Recent Earnings
Cardiff Oncology, Inc. (CRDF) EPS & revenue vs analyst estimates — last 4 quarters
●Beat EPS 8/12 qtrs (67%)●Beat Revenue 11/12 qtrs (92%)
Q2 2026Latest
May 14, 2026EPS
$0.18
Est $0.13
-38.5%
Revenue
$41,000
Est $88,571
-53.7%
Q1 2026
Feb 24, 2026EPS
$0.11
Est $0.18
+38.9%
Revenue
$243,000
Est $103,500
+134.8%
Q4 2025
Nov 6, 2025EPS
$0.17
Est $0.20
+15.0%
Revenue
$120,000
Est $103,500
+15.9%
Q3 2025
Jul 29, 2025EPS
$0.21
Est $0.19
-10.5%
Revenue
$121,000
Est $109,375
+10.6%
| Quarter | Date | EPS (Act vs Est) | Revenue (Act vs Est) |
|---|---|---|---|
| Q2 2026Latest | May 14, 2026 | $0.18vs $0.13-38.5% | $41,000vs $88,571-53.7% |
| Q1 2026 | Feb 24, 2026 | $0.11vs $0.18+38.9% | $243,000vs $103,500+134.8% |
| Q4 2025 | Nov 6, 2025 | $0.17vs $0.20+15.0% | $120,000vs $103,500+15.9% |
| Q3 2025 | Jul 29, 2025 | $0.21vs $0.19-10.5% | $121,000vs $109,375+10.6% |
Based on last 12 quarters of dataView full earnings history →
CRDF Peer Comparison
Cardiff Oncology, Inc. (CRDF) competitors in Oncology Therapeutics Developers — business model, growth, and fundamentals comparison
| Company | Market Cap | Stock Price | P/E Ratio (TTM) | Revenue Growth 1Y | Net Margin | Return on Equity (ROE) | FCF Yield | Debt / Equity |
|---|---|---|---|---|---|---|---|---|
 TGTX | 7.36B | 48.05 | 17.35 | 87.32% | 65.95% | 87.36% | 0.40 | |
 MGNX | 254.89M | 4.01 | -3.40 | 0.78% | -44.79% | -147.8% | 1.92 | |
 NKTR | 1.16B | 59.21 | -6.09 | -43.89% | -284.18% | -87% | 1.66 | |
 IMVT | 6.75B | 32.88 | -11.87 | -68.16% | 0.00 | |||
 KPTI | 76.84M | 9.00 | -0.50 | 0.57% | -129.02% | |||
 AGIO | 1.71B | 28.72 | -4.03 | 48.03% | -6.4% | -34.11% | 0.05 | |
 AGEN | 141.17M | 3.39 | -997.06 | 10.37% | 52.16% | |||
 FATE | 229.62M | 1.97 | -1.71 | -51.24% | -20.57% | -58.89% | 0.38 |
Compare CRDF vs Peers
Cardiff Oncology, Inc. (CRDF) vs competitors — business, growth, and fundamentals comparison against the closest industry rivals.
CRDF Income Statement
Cardiff Oncology, Inc. (CRDF) annual income statement — 10-year revenue, gross profit & net income history
10Y historyFree accessUpdated daily
| Metric | Dec'17 | Dec'18 | Dec'19 | Dec'20 | Dec'21 | Dec'22 | Dec'23 | Dec'24 | Dec'25 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|
Sales/Revenue | 505K | 378K | 244.63K | 366K | 359K | 386K | 488K | 683K | 593K | 525K |
Revenue Growth % | 32.55% | -25.15% | -35.28% | 49.61% | -1.91% | 7.52% | 26.42% | 39.96% | -13.18% | -10.71% |
Cost of Goods Sold | 1.81M | 597K | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 11.8M |
COGS % of Revenue | 358.61% | 157.94% | - | - | - | - | - | - | - | - |
Gross Profit | -1.31M▲ 0% | -219K▲ 83.2% | 244.63K▲ 211.7% | 366K▲ 49.6% | 359K▼ 1.9% | 386K▲ 7.5% | 488K▲ 26.4% | 683K▲ 40.0% | 593K▼ 13.2% | -11.28M▲ 0% |
Gross Margin % | -258.61% | -57.94% | 100% | 100% | 100% | 100% | 100% | 100% | 100% | -2147.81% |
Gross Profit Growth % | 3.19% | 83.23% | 211.7% | 49.61% | -1.91% | 7.52% | 26.42% | 39.96% | -13.18% | - |
Operating Expenses | 22.11M | 16.17M | 16.92M | 19.45M | 29.21M | 40.29M | 45.9M | 49.33M | 49.55M | 36.15M |
OpEx % of Revenue | 4379.21% | 4277.78% | 6917.79% | 5314.75% | 8137.6% | 10437.31% | 9405.74% | 7223.13% | 8356.32% | - |
Selling, General & Admin | 14.23M | 8.01M | 5.76M | 8.22M | 11.84M | 13.18M | 13.04M | 12.48M | 14.22M | 13.02M |
SG&A % of Revenue | 2818.22% | 2117.99% | 2354.92% | 2245.08% | 3297.49% | 3414.77% | 2672.75% | 1827.53% | 2398.65% | - |
Research & Development | 7.88M | 8.16M | 11.16M | 11.23M | 17.38M | 27.11M | 32.86M | 36.85M | 35.33M | 31.62M |
R&D % of Revenue | 1560.99% | 2159.79% | 4562.87% | 3069.67% | 4840.11% | 7022.54% | 6732.99% | 5395.61% | 5957.67% | - |
Other Operating Expenses | -170K | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | -1.22M |
Operating Income | -25.6M▲ 0% | -17.05M▲ 33.4% | -16.68M▲ 2.2% | -19.09M▼ 14.4% | -28.86M▼ 51.2% | -39.9M▼ 38.3% | -45.41M▼ 13.8% | -48.65M▼ 7.1% | -48.96M▼ 0.6% | -47.43M▲ 0% |
Operating Margin % | -5068.51% | -4511.38% | -6817.79% | -5214.75% | -8037.6% | -10337.31% | -9305.74% | -7123.13% | -8256.32% | -9033.9% |
Operating Income Growth % | 36.24% | 33.38% | 2.2% | -14.43% | -51.18% | -38.28% | -13.81% | -7.13% | -0.64% | - |
EBITDA | -24.54M | -16.32M | -16.18M | -18.62M | -28.4M | -39.67M | -45.01M | -48.25M | -48.06M | -46.4M |
EBITDA Margin % | -4859.82% | -4316.64% | -6615.76% | -5087.43% | -7911.98% | -10276.17% | -9224.18% | -7063.98% | -8103.88% | -8837.33% |
EBITDA Growth % | 37.19% | 33.51% | 0.81% | -15.05% | -52.55% | -39.65% | -13.48% | -7.18% | 0.4% | 10.03% |
D&A (Non-Cash Add-back) | 1.05M | 736.09K | 494.23K | 466K | 451K | 236K | 398K | 404K | 904K | 1.03M |
EBIT | -23.87M | -16.44M | -16.41M | -19.3M | -28.86M | -39.9M | -45.41M | -48.65M | -48.96M | -46.71M |
Net Interest Income | -886.06K | 194.02K | 234.17K | 88K | 264K | 1.58M | 4.07M | 3.26M | 3.1M | 2.67M |
Interest Income | 147.88K | 219.43K | 234.17K | 90K | 264K | 1.58M | 4.07M | 3.26M | 3.1M | 2.67M |
Interest Expense | 1.03M | 25.41K | 0 | 2K | 0 | 0 | 0 | 0 | 0 | 0 |
Other Income/Expense | 689.05K | -72.45K | 264.33K | -221K | 564K | 1.2M | 3.97M | 3.22M | 3.11M | 2.67M |
Pretax Income | -24.91M▲ 0% | -16.46M▲ 33.9% | -16.41M▲ 0.3% | -19.31M▼ 17.6% | -28.29M▼ 46.5% | -38.7M▼ 36.8% | -41.44M▼ 7.1% | -45.43M▼ 9.6% | -45.85M▼ 0.9% | -44.77M▲ 0% |
Pretax Margin % | -4932.08% | -4354.76% | -6709.74% | -5275.14% | -7880.5% | -10026.94% | -8492.01% | -6651.68% | -7732.04% | -8527.24% |
Income Tax | 716K | 617.64K | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Effective Tax Rate % | -2.87% | -3.75% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% |
Net Income | -24.91M▲ 0% | -16.46M▲ 33.9% | -16.41M▲ 0.3% | -19.31M▼ 17.6% | -28.29M▼ 46.5% | -38.7M▼ 36.8% | -41.44M▼ 7.1% | -45.43M▼ 9.6% | -45.85M▼ 0.9% | -44.77M▲ 0% |
Net Margin % | -4932.08% | -4354.76% | -6709.74% | -5275.14% | -7880.5% | -10026.94% | -8492.01% | -6651.68% | -7732.04% | -8527.24% |
Net Income Growth % | 36.47% | 33.91% | 0.28% | -17.62% | -46.53% | -36.81% | -7.07% | -9.63% | -0.92% | 8.36% |
Net Income (Continuing) | -24.91M | -16.46M | -16.41M | -19.31M | -28.29M | -38.7M | -41.44M | -45.43M | -45.85M | -44.77M |
Discontinued Operations | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Minority Interest | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
EPS (Diluted) | -51.71▲ 0% | -7.06▲ 86.3% | -2.70▲ 61.8% | -1.08▲ 60.0% | -0.73▲ 32.4% | -0.89▼ 21.9% | -0.93▼ 4.5% | -0.95▼ 2.2% | -0.69▲ 27.4% | -0.66▲ 0% |
EPS Growth % | 44.53% | 86.35% | 61.76% | 60% | 32.41% | -21.92% | -4.49% | -2.15% | 27.37% | 35.58% |
EPS (Basic) | -51.71 | -7.06 | -2.70 | -1.08 | -0.73 | -0.89 | -0.93 | -0.95 | -0.69 | - |
Diluted Shares Outstanding | 481.67K | 2.33M | 5.97M | 20.88M | 39.03M | 43.6M | 44.68M | 47.65M | 66.84M | 68.35M |
Basic Shares Outstanding | 481.67K | 2.33M | 5.97M | 20.88M | 39.03M | 43.6M | 44.68M | 47.65M | 66.84M | 68.35M |
Dividend Payout Ratio | - | - | - | - | - | - | - | - | - | - |
CRDF Balance Sheet
Cardiff Oncology, Inc. (CRDF) balance sheet — assets, liabilities & shareholders' equity
| Metric | Dec'17 | Dec'18 | Dec'19 | Dec'20 | Dec'21 | Dec'22 | Dec'23 | Dec'24 | Dec'25 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|
Total Current Assets | 9.47M | 12.77M | 11.35M | 133.36M | 146.13M | 111.28M | 77.41M | 95.05M | 60.13M | 47.34M |
Cash & Short-Term Investments | 8.23M | 11.45M | 10.2M | 130.98M | 140.82M | 105.27M | 74.82M | 91.75M | 58.3M | 46.06M |
Cash Only | 8.23M | 11.45M | 10.2M | 130.98M | 11.94M | 16.35M | 21.66M | 51.47M | 17.47M | 8.54M |
Short-Term Investments | 0 | 0 | 0 | 0 | 128.88M | 88.92M | 53.17M | 40.28M | 40.83M | 37.51M |
Accounts Receivable | 77.09K | 167.75K | 203.48K | 320K | 535K | 771K | 288K | 773K | 182K | 191K |
Days Sales Outstanding | 55.72 | 161.99 | 303.6 | 319.13 | 543.94 | 729.05 | 215.41 | 413.1 | 112.02 | 200.4 |
Inventory | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Days Inventory Outstanding | - | - | - | - | - | - | - | - | - | - |
Other Current Assets | 0 | 0 | 0 | 0 | 0 | 5.25M | 2.3M | 2.54M | 1.64M | 1.09M |
Total Non-Current Assets | 2.82M | 1.41M | 1.73M | 1.37M | 3.42M | 4.91M | 4.22M | 2.14M | 1.76M | 1.83M |
Property, Plant & Equipment | 2.43M | 1.3M | 1.58M | 967K | 3.18M | 3.52M | 2.95M | 2.07M | 1.21M | 986K |
Fixed Asset Turnover | 0.21x | 0.29x | 0.16x | 0.38x | 0.11x | 0.11x | 0.17x | 0.33x | 0.49x | 0.40x |
Goodwill | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Intangible Assets | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Long-Term Investments | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Other Non-Current Assets | 390K | 103K | 157.58K | 404K | 239K | 1.39M | 1.28M | 69K | 549K | 844K |
Total Assets | 12.29M▲ 0% | 14.17M▲ 15.4% | 13.09M▼ 7.7% | 134.73M▲ 929.5% | 149.54M▲ 11.0% | 116.19M▼ 22.3% | 81.64M▼ 29.7% | 97.19M▲ 19.1% | 61.88M▼ 36.3% | 49.17M▲ 0% |
Asset Turnover | 0.04x | 0.03x | 0.02x | 0.00x | 0.00x | 0.00x | 0.01x | 0.01x | 0.01x | 0.01x |
Asset Growth % | -72.05% | 15.36% | -7.66% | 929.51% | 11% | -22.3% | -29.74% | 19.05% | -36.33% | -62.27% |
Total Current Liabilities | 3.95M | 2.96M | 4.78M | 6.12M | 6.56M | 7.81M | 10.44M | 13.43M | 16.39M | 14.46M |
Accounts Payable | 825.24K | 664.84K | 656.3K | 1.37M | 1.44M | 1.96M | 1.97M | 4.82M | 8.09M | 5.48M |
Days Payables Outstanding | 166.32 | 406.48 | - | - | - | - | - | - | - | 170.25 |
Short-Term Debt | 1.33M | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Deferred Revenue (Current) | -11 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Other Current Liabilities | 651.2K | 827.65K | 1M | 1.56M | 1.48M | 1.85M | 5.05M | 2.75M | 7.58M | 8.34M |
Current Ratio | 2.40x | 4.31x | 2.37x | 21.79x | 22.28x | 14.25x | 7.41x | 7.08x | 3.67x | 3.27x |
Quick Ratio | 2.40x | 4.31x | 2.37x | 21.79x | 22.28x | 14.25x | 7.41x | 7.08x | 3.67x | 3.27x |
Cash Conversion Cycle | - | - | - | - | - | - | - | - | - | 30.15 |
Total Non-Current Liabilities | 1.83M | 1.12M | 993.46K | 450K | 2.57M | 2.04M | 1.46M | 813K | 102K | 0 |
Long-Term Debt | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Capital Lease Obligations | 0 | 0 | 860.96K | 9K | 2.57M | 2.04M | 1.46M | 813K | 102K | 850K |
Deferred Tax Liabilities | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Other Non-Current Liabilities | 1.83M | 1.12M | 132.5K | 441K | 0 | 0 | 0 | 0 | 0 | 0 |
Total Liabilities | 5.78M | 4.09M | 5.78M | 6.57M | 9.13M | 9.85M | 11.9M | 14.24M | 16.5M | 14.46M |
Total Debt | 1.33M | 0 | 1.73M | 869K | 3.12M | 2.71M | 2.15M | 1.52M | 832K | 646K |
Net Debt | -6.89M | -11.45M | -8.47M | -130.11M | -8.82M | -13.63M | -19.51M | -49.95M | -16.64M | -7.9M |
Debt / Equity | 0.20x | - | 0.24x | 0.01x | 0.02x | 0.03x | 0.03x | 0.02x | 0.02x | 0.02x |
Debt / EBITDA | - | - | - | - | - | - | - | - | - | -0.01x |
Net Debt / EBITDA | - | - | - | - | - | - | - | - | - | 0.17x |
Interest Coverage | -23.09x | -646.85x | - | -9652.50x | - | - | - | - | - | - |
Total Equity | 6.51M▲ 0% | 10.08M▲ 55.0% | 7.31M▼ 27.5% | 128.16M▲ 1652.9% | 140.42M▲ 9.6% | 106.34M▼ 24.3% | 69.74M▼ 34.4% | 82.95M▲ 18.9% | 45.39M▼ 45.3% | 34.71M▲ 0% |
Equity Growth % | -67.09% | 55% | -27.5% | 1652.87% | 9.57% | -24.27% | -34.42% | 18.94% | -45.28% | -85.66% |
Book Value per Share | 13.51 | 4.33 | 1.22 | 6.14 | 3.60 | 2.44 | 1.56 | 1.74 | 0.68 | 0.51 |
Total Shareholders' Equity | 6.51M | 10.08M | 7.31M | 128.16M | 140.42M | 106.34M | 69.74M | 82.95M | 45.39M | 34.71M |
Common Stock | 5.28K | 7.74K | 8.31K | 4K | 4K | 4K | 4K | 7K | 7K | 7K |
Retained Earnings | -173.05M | -192.19M | -208.9M | -231.5M | -259.81M | -298.1M | -339.54M | -384.18M | -430.03M | -442.38M |
Treasury Stock | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Accumulated OCI | -2.07M | -2.11M | 0 | 0 | -142K | -395K | -67K | 34K | 50K | -49K |
Minority Interest | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
CRDF Cash Flow Statement
Cardiff Oncology, Inc. (CRDF) cash flow — operating, investing & free cash flow history
| Metric | Dec'17 | Dec'18 | Dec'19 | Dec'20 | Dec'21 | Dec'22 | Dec'23 | Dec'24 | Dec'25 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|
Cash from Operations | -23.28M | -13.2M | -13.27M | -16.32M | -23.04M | -33.82M | -30.89M | -37.69M | -37.92M | -37.42M |
Operating CF Margin % | -4610.1% | -3492.06% | -5423.66% | -4457.65% | -6417.83% | -8761.66% | -6329.3% | -5518.74% | -6395.11% | - |
Operating CF Growth % | 25% | 43.3% | -0.52% | -22.96% | -41.22% | -46.79% | 8.67% | -22.04% | -0.61% | 51.99% |
Net Income | -24.91M | -16.46M | -16.41M | -19.31M | -28.29M | -38.7M | -41.44M | -45.43M | -45.85M | -44.77M |
Depreciation & Amortization | 1.25M | 859K | 494K | 466K | 451K | 236K | 398K | 404K | 904K | 1.17M |
Stock-Based Compensation | 4.01M | 2.17M | 885K | 1.76M | 3.23M | 4.26M | 4.51M | 4.76M | 5.69M | 5.99M |
Deferred Taxes | -1.75M | -635K | -28K | 0 | 1.32M | 0 | 0 | 0 | 0 | 0 |
Other Non-Cash Items | 1.24M | 764K | 703K | 1.42M | 2.03M | 772K | -921K | -598K | -848K | -804K |
Working Capital Changes | -3.13M | 98K | 1.09M | -654K | -1.79M | -380K | 6.57M | 3.17M | 2.18M | 994K |
Change in Receivables | 23.36K | 19.26M | -35.73M | -117K | -215K | -236K | 483K | -484K | 591K | 214K |
Change in Inventory | 0 | -255.62M | -1.42B | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Change in Payables | -2.94B | 236.48M | 1.46B | 0 | 719K | 1.35M | 2.83M | 2.98M | 2.2M | 5.21M |
Cash from Investing | 23.96M | 23K | -68K | -211K | -131.45M | 38.15M | 36.2M | 13.73M | 1.34M | 19.18M |
Capital Expenditures | -100K | -5.1K | -68K | -211K | -205K | -892K | -582K | -80K | -44K | -44K |
CapEx % of Revenue | 19.8% | 1.35% | 27.8% | 57.65% | 57.1% | 231.09% | 119.26% | 11.71% | 7.42% | 8.38% |
Acquisitions | 109.91M | 5.1K | 0 | 0 | 205K | -114K | 0 | 0 | 0 | 0 |
Investments | - | - | - | - | - | - | - | - | - | - |
Other Investing | -101.1M | 23K | 0 | 0 | -205K | 114K | 0 | 0 | -744K | -744K |
Cash from Financing | -6.38M | 16.4M | 12.08M | 137.31M | 35.45M | 75K | 0 | 53.78M | 2.58M | 2.68M |
Debt Issued (Net) | -17.24M | -1.38M | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Equity Issued (Net) | 11.73M | 16.17M | 8.82M | 112.3M | 34.19M | 75K | 0 | 53.41M | 2.58M | 2.66M |
Dividends Paid | -24.24M | -24.24M | -24.24M | 0 | -24K | -414K | 0 | 0 | 0 | 0 |
Share Repurchases | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Other Financing | -866.04K | 25.85M | 27.5M | 25.01M | 1.29M | 414K | 0 | 373K | 0 | 25K |
Net Change in Cash | -5.69M▲ 0% | 3.23M▲ 156.7% | -1.26M▼ 139.0% | 120.79M▲ 9701.4% | -119.04M▼ 198.6% | 4.4M▲ 103.7% | 5.31M▲ 20.5% | 29.82M▲ 461.7% | -34M▼ 214.0% | -15.55M▲ 0% |
Free Cash Flow | -23.38M▲ 0% | -13.21M▲ 43.5% | -13.34M▼ 1.0% | -16.53M▼ 23.9% | -23.25M▼ 40.7% | -34.71M▼ 49.3% | -31.47M▲ 9.3% | -37.77M▼ 20.0% | -37.97M▼ 0.5% | -37.46M▲ 0% |
FCF Margin % | -4629.9% | -3493.41% | -5451.45% | -4515.3% | -6474.93% | -8992.75% | -6448.57% | -5530.45% | -6402.53% | -7135.43% |
FCF Growth % | 26.62% | 43.52% | -0.99% | -23.92% | -40.66% | -49.33% | 9.34% | -20.03% | -0.51% | 12.37% |
FCF per Share | -48.54 | -5.67 | -2.23 | -0.79 | -0.60 | -0.80 | -0.70 | -0.79 | -0.57 | -0.55 |
FCF Conversion (FCF/Net Income) | 0.93x | 0.80x | 0.81x | 0.85x | 0.81x | 0.87x | 0.75x | 0.83x | 0.83x | 0.84x |
Interest Paid | 668.47K | 22.48K | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Taxes Paid | 800 | 800 | 800 | 1K | 1K | 2K | 1K | 0 | 0 | 0 |
CRDF Key Ratios
Cardiff Oncology, Inc. (CRDF) financial ratios — P/E, ROE, debt and 30+ core market and balance-sheet ratios
| Metric | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|
| Return on Equity (ROE) | -189.59% | -198.44% | -188.72% | -28.5% | -21.07% | -31.37% | -47.07% | -59.51% | -71.45% | -95.51% |
| Return on Invested Capital (ROIC) | - | - | - | - | -33.39% | -26.68% | -47.65% | -87.68% | -118.93% | -98.65% |
| Gross Margin | -258.61% | -57.94% | 100% | 100% | 100% | 100% | 100% | 100% | 100% | -2147.81% |
| Net Margin | -4932.08% | -4354.76% | -6709.74% | -5275.14% | -7880.5% | -10026.94% | -8492.01% | -6651.68% | -7732.04% | -8527.24% |
| Debt / Equity | 0.20x | - | 0.24x | 0.01x | 0.02x | 0.03x | 0.03x | 0.02x | 0.02x | 0.02x |
| Interest Coverage | -23.09x | -646.85x | - | -9652.50x | - | - | - | - | - | - |
| FCF Conversion | 0.93x | 0.80x | 0.81x | 0.85x | 0.81x | 0.87x | 0.75x | 0.83x | 0.83x | 0.84x |
| Revenue Growth | 32.55% | -25.15% | -35.28% | 49.61% | -1.91% | 7.52% | 26.42% | 39.96% | -13.18% | -10.71% |
Related:CRDF Dividend History·CRDF Revenue History·CRDF Price History·CRDF P/E History·CRDF Financial Ratios·CRDF Institutional Holders
CRDF SEC Filings & Documents
Cardiff Oncology, Inc. (CRDF) SEC filings — annual & quarterly reports (10-K, 10-Q)
CRDF Frequently Asked Questions
Cardiff Oncology, Inc. (CRDF) stock FAQ — growth, dividends, profitability & financials explained
Growth & Financials
Cardiff Oncology, Inc. (CRDF) reported $0.5M in revenue for fiscal year 2025.
Cardiff Oncology, Inc. (CRDF) saw revenue decline by 13.2% over the past year.
Cardiff Oncology, Inc. (CRDF) reported a net loss of $44.8M for fiscal year 2025.
Dividend & Returns
Cardiff Oncology, Inc. (CRDF) has a return on equity (ROE) of -71.5%. Negative ROE indicates the company is unprofitable.
Cardiff Oncology, Inc. (CRDF) had negative free cash flow of $37.5M in fiscal year 2025, likely due to heavy capital investments.